B N Manohar | CEO
Stempeutics Research | India

B N Manohar, CEO, Stempeutics Research

Manohar is the MD & CEO of Stempeutics Research – a leading stem cell research and product development company in India. He earned his B.E. degree in Electronics & Communication from REC Trichy in 1977. Post that he did M.E. in Computer Science from College of Engineering, Guindy. 
Manohar has transformed Stempeutics – a life science start-up from R&D to Commercialization stage with Global recognition. Stempeutics has developed an innovative drug called “Stempeucel” for addressing major unmet medical needs in India and Globally. This drug developed by an Indian company has received many Global Recognitions. Eight countries including US & Japan has granted patent for the novelty and inventiveness of the drug. Europe has recognized this drug by granting Advanced Therapy Medicinal Product classification and Orphan Drug Designation. Recently it became the FIRST stem cell product to be approved (limited approval) by Indian FDA for treating patients suffering from life threatening disease call Buerger’s Disease. Stempeutics has put India on the “World map of Regenerative Medicine”. Under Manohar’s leadership Stempeutics has been recognized as India’s hottest startups by Business Today in 2008 and Karnataka Government bestowed “Emerging Company of the Year award” in 2011 and 2013. He raised US$ 10M in 2009 by establishing strategic alliance with major pharma Cipla.

Appearances:



Phar-East Day Two @ 11:50

Cell Therapy for treating Critical Limb Ischemia – an unmet medical need

Critical Limb Ischemia (CLI) is a Peripheral arterial disease (PAD) in the legs, sometimes known as peripheral vascular disease, is frequently caused by atheroma (fatty deposits) in the walls of the arteries, leading to insufficient blood flow to the muscles and other tissues. CLI is a major healthcare issue worldwide and patients with CLI have an increased risk of mortality, myocardial infarction and cerebrovascular disease. The predicted increase in the prevalence of CLI will intensify the demands placed on the healthcare services in India and around the globe. There is therefore a pressing need within the healthcare system to commence an effective therapeutic strategy for treating patients with CLI. Stem Cell therapy likely to address the gaps in the treatment of CLI due to 1) Anti –inflammatory properties 2) Ability to promote neovascularization and 3) promote healing of non-healing ischemic ulcers.

back to speakers